Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jaeho Jung"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Background4-1BB (CD137) is a co-stimulatory receptor that stimulates the function of multiple immune cells. Its ability to induce potent anti-tumor activity makes 4-1BB an attractive target for immuno-oncology. However, clinical development of a mono
Autor:
Hyung-Seung Jin, Gihoon You, Hyunjoo Kim, Yangmi Lim, Jung Uijung, Jeon Jaehyoung, Eunsil Sung, Shinai Lee, Jaeho Jung, Jiang Wenqing, Zhengyi Wang, Jonghwa Won, Kim Youngkwang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPD-(L)1 inhibitor has revolutionized cancer treatment, but there are unmet clinical needs for PD-(L)1 inhibitor-resistant/refractory patients. Activation of T cells in tumor microenvironment by 4-1BB agonist antibodies is one of the promisi
Autor:
Minwoo Jeon, Han-Byul Lee, Seongju Jeong, Shin Hwang, Hyung-Don Kim, Zhengyi Wang, Hyunjoo Kim, Su-Hyung Park, Eun-Sil Sung, Jung Uijung, Jeon Jaehyoung, Eui-Cheol Shin, Yangmi Lim, Shinai Lee, Jiang Wenqing, Kim Youngkwang, Eunyoung Park, Youngeun Hong, Fang Lei, Son Yonggyu, Jonghwa Won, Jaeho Jung
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundStimulation of 4-1BB with agonistic antibodies is a promising strategy for improving the therapeutic efficacy of immune checkpoint inhibitors (ICIs) or for overcoming resistance to ICIs. However, dose-dependent hepatotoxicity was observed i